Moriniere P - Search Results

1

Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia.

Fournier A, Moriniere P, Sebert JL, Dkhissi H, Atik A, Leflon P, Renaud H, Gueris J, Gregoire I, Idrissi A, et al. Fournier A, et al. Among authors: moriniere p. Kidney Int Suppl. 1986 Feb;18:S114-9. Kidney Int Suppl. 1986. PMID: 3457987 No abstract available.

2

Calcium carbonate and magnesium hydroxide in the prevention of renal osteodystrophy or the demise of aluminum toxicity in uremia. Analysis of 5 years experience.

Morinière P, Fournier A, Westeel PF, Idrissi A, Renaud H, Hocine C, Belbrik S, Marie A, Leflon P, Sebert JL. Morinière P, et al. Contrib Nephrol. 1988;64:58-73. doi: 10.1159/000415728. Contrib Nephrol. 1988. PMID: 3053039 Review. No abstract available.

3

Aluminum load and histological bone disease in hemofiltration and hemodialysis.

Fournier A, Moriniere P, Fohrer P, Leflon P, de Fremont JF, Marié A, Westeel PF, Renaud H, Tahiri Y, Idrissi A, et al. Fournier A, et al. Among authors: moriniere p. Kidney Int Suppl. 1988 Mar;24:S168-70. Kidney Int Suppl. 1988. PMID: 3163040 No abstract available.

4

Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.

Morinière P, Fournier A, Leflon A, Hervé M, Sebert JL, Grégoire I, Bataille P, Guéris J. Morinière P, et al. Nephron. 1985;39(4):309-15. doi: 10.1159/000183396. Nephron. 1985. PMID: 3982576 Clinical Trial.

5

Long-term efficacy and safety of oral calcium as compared to A1(OH)3 as phosphate binders.

Moriniere P, Hocine C, Boudailliez B, Belbrik S, Renaud H, Westeel PF, Solal MC, Fournier A. Moriniere P, et al. Kidney Int Suppl. 1989 Nov;27:S133-5. Kidney Int Suppl. 1989. PMID: 2636648 No abstract available.

6

1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialyzed patients taking Al(OH)3.

Demontis R, Westeel PF, Boudalliez B, Moriniere P, Leflon A, Abdulmassih Z, Atik H, Renaud H, Fournier A. Demontis R, et al. Among authors: moriniere p. Kidney Int Suppl. 1988 Mar;24:S175-7. Kidney Int Suppl. 1988. PMID: 3163043 No abstract available.

7

Evaluation of vascular calcinosis risk factors in patients on chronic hemodialysis: lack of influence of calcium carbonate.

Renaud H, Atik A, Hervé M, Morinière P, Hocine C, Belbrik S, Fournier A. Renaud H, et al. Among authors: moriniere p. Nephron. 1988;48(1):28-32. doi: 10.1159/000184864. Nephron. 1988. PMID: 3340252

8

The approach to the treatment of secondary hyperparathyroidism in early renal failure.

Fournier A, Morinière P, Renaud H. Fournier A, et al. Among authors: moriniere p. Am J Nephrol. 1988;8(2):170-2. doi: 10.1159/000167577. Am J Nephrol. 1988. PMID: 3394724 No abstract available.

9

Magnesium hydroxide is a useful complementary aluminum-free phosphate binder to moderate doses of oral calcium in uremic patients on chronic hemodialysis.

Fournier A, Moriniere P. Fournier A, et al. Among authors: moriniere p. Clin Nephrol. 1988 Jun;29(6):319. Clin Nephrol. 1988. PMID: 3396236 No abstract available.

10

Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism.

Moriniere P, Roussel A, Tahiri Y, de Fremont JF, Maurel G, Jaudon MC, Gueris J, Fournier A. Moriniere P, et al. Proc Eur Dial Transplant Assoc. 1983;19:784-7. Proc Eur Dial Transplant Assoc. 1983. PMID: 6878265

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

125 results

Search Page

Filters